Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol.
ependymoma
overall survival
progression free survival
randomized controlled trial
treatments
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
03
2022
accepted:
19
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
The clinical management of ependymoma in childhood and adolescence is complex and the clinicobiopathological correlates of outcome remain poorly understood. This international SIOP Ependymoma II (SIOP EPII) trial aims to improve the outcome of patients with ependymoma. SIOP EPII includes any patient <22 years at diagnosis with ependymoma, stratified by age, tumor location, and outcome of the initial surgery. Centralized pathology and imaging is required for diagnosis confirmation. SIOP EPII included three randomized studies according to age, postoperative residue, and suitability to receive radiotherapy. Patients ineligible for interventional strata are followed-up in an observational study. The staging phase aims to determine if central neurosurgical and radiological postoperative MRI reviews increase the resection rate. Patients ≥ ClinicalTrials.gov, identifier: NCT02265770.
Sections du résumé
Background
UNASSIGNED
The clinical management of ependymoma in childhood and adolescence is complex and the clinicobiopathological correlates of outcome remain poorly understood. This international SIOP Ependymoma II (SIOP EPII) trial aims to improve the outcome of patients with ependymoma.
Methods
UNASSIGNED
SIOP EPII includes any patient <22 years at diagnosis with ependymoma, stratified by age, tumor location, and outcome of the initial surgery. Centralized pathology and imaging is required for diagnosis confirmation. SIOP EPII included three randomized studies according to age, postoperative residue, and suitability to receive radiotherapy. Patients ineligible for interventional strata are followed-up in an observational study. The staging phase aims to determine if central neurosurgical and radiological postoperative MRI reviews increase the resection rate. Patients ≥
Clinical Trial Registration
UNASSIGNED
ClinicalTrials.gov, identifier: NCT02265770.
Identifiants
pubmed: 35720069
doi: 10.3389/fneur.2022.887544
pmc: PMC9201444
doi:
Banques de données
ClinicalTrials.gov
['NCT02265770']
Types de publication
Journal Article
Langues
eng
Pagination
887544Informations de copyright
Copyright © 2022 Leblond, Massimino, English, Ritzmann, Gandola, Calaminus, Thomas, Pérol, Gautier, Grundy and Frappaz.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Childs Nerv Syst. 2016 Nov;32(11):2189-2196
pubmed: 27585992
Pediatr Blood Cancer. 2021 Aug;68(8):e28930
pubmed: 33565268
Acta Neuropathol. 2018 Aug;136(2):211-226
pubmed: 29909548
Eur J Paediatr Neurol. 2019 Jul;23(4):560-570
pubmed: 31182404
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):166-173
pubmed: 30102193
Cancer. 2019 Jun 1;125(11):1867-1876
pubmed: 30768777
J Neurooncol. 2012 Jan;106(2):367-75
pubmed: 21826561
Childs Nerv Syst. 2019 Mar;35(3):411-420
pubmed: 30554263
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95
pubmed: 10661334
J Neurosurg Pediatr. 2013 Jun;11(6):673-81
pubmed: 23540528
Eur J Paediatr Neurol. 2015 Mar;19(2):202-10
pubmed: 25617909
Neuro Oncol. 2016 Oct;18(10):1451-60
pubmed: 27194148
J Neurosurg Pediatr. 2011 Sep;8(3):246-50
pubmed: 21882914
J Clin Oncol. 2001 Mar 1;19(5):1288-96
pubmed: 11230470
Neuro Oncol. 2021 May 5;23(5):848-857
pubmed: 33135735
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Neuro Oncol. 2022 Jun 1;24(6):936-948
pubmed: 35018471
Neuro Oncol. 2021 Jun 1;23(6):874-876
pubmed: 33728470
Neuro Oncol. 2019 Oct 9;21(10):1319-1330
pubmed: 30976811
Pediatr Blood Cancer. 2020 Sep;67(9):e28426
pubmed: 32614133
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Lancet Oncol. 2009 Mar;10(3):258-66
pubmed: 19274783
J Clin Oncol. 2019 Apr 20;37(12):974-983
pubmed: 30811284
J Neurooncol. 2009 Sep;94(3):391-8
pubmed: 19330288
Lancet Oncol. 2007 Aug;8(8):696-705
pubmed: 17644039
ESMO Open. 2021 Aug;6(4):100174
pubmed: 34139485